HUMACYTE INC
HUMA · NASDAQ
Updated at 2026-10-13 15:06:24
- Today's High
- $0.39
- Today’s Low
- $0.36
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $0.40
- Previous Close
- $0.38
- Volume
- 16.34M
- Market Cap
- $108.23M
- P/E Ratio
- --
- EPS
- $-0.48
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, NC, UNITED STATES, 27713
- Country
- US
- Listing Date
- 2020-09-22
- Fiscal Year End
- December
- Shares Outstanding
- 269.64M
- CIK
- 0001818382
- Website
- humacyte.com
Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs). These innovative, off-the-shelf products are designed to meet pressing needs in vascular reconstruction and chronic disease management, improving patient outcomes and potentially reducing healthcare expenses. Leveraging its advanced technology platform, Humacyte is strategically positioned to drive innovation in transplantation and tissue engineering, thereby cementing its status as a transformative leader within the rapidly evolving landscape of medical therapies.
Financial Metrics
Revenue
2026-06-30
$406K
2026-03-31
$495K
2025-12-31
$467K
2025-09-30
$753K
Operating Expenses
2026-06-30
$26.17M
2026-03-31
$27.39M
2025-12-31
$20.43M
2025-09-30
$23.01M
Net Income
2026-06-30
-$36.8M
2026-03-31
-$17.61M
2025-12-31
-$24.8M
2025-09-30
-$17.51M
Net Profit Margin
2026-06-30
-9.06K%
2026-03-31
-3.55K%
2025-12-31
-5.31K%
2025-09-30
-2.32K%
Earnings Per Share
2026-06-30
$-0.16
2026-03-31
$-0.09
2025-12-31
$-0.18
2025-09-30
$-0.11
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$32.69M
2026-03-31
-$13.55M
2025-12-31
-$19.92M
2025-09-30
-$13.03M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $406K | $495K | $467K | $753K |
| Operating Expenses | $26.17M | $27.39M | $20.43M | $23.01M |
| Net Income | -$36.8M | -$17.61M | -$24.8M | -$17.51M |
| Net Profit Margin | -9.06K% | -3.55K% | -5.31K% | -2.32K% |
| Earnings Per Share | $-0.16 | $-0.09 | $-0.18 | $-0.11 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$32.69M | -$13.55M | -$19.92M | -$13.03M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.